Oral Cancer News

Emergence of nanobiotechnology

Source: www.thedailystar.net Author: Md. Riajul Hossain Think of the tiny robots swimming through your blood vessels all over your body and fighting your enemies. Fascinating! Isn't it? The picture you are having in your mind right at this moment could be possible only because of the blessings of nanotechnology. When you apply genetic engineering in microorganisms, say bacteria, to attain your goal of curing various types of problems that living organisms might have, can be termed as nanobiotechnology. To define nanotechnology, it is stated that nanotechnology is the understanding and control of matter at dimensions between approximately 1 and 100 nanometers, where unique phenomena enable novel applications. Nanoparticles are actually much too small to see with your eyes, or even with a typical light microscope. At the nanoscale, materials can behave in different and unexpected ways. For example, gold is yellow in color, but at the microscale of 25 nm size, they appear red. The target of the researchers in this field is to harness these different and unexpected behaviors of the nanoparticles to make new technologies, namely nanotechnology. Today, we will see how nanotechnology can involve biotechnology and what nanobiotechnology has to offer for us. You need not necessarily engineer microbes for nanobiotechnology every time. Even small nanoparticles could be used to deliver drugs in human bodies, to clear environmental pollutants etc. all of which could be taken under the umbrella of nanobiotechnology. This technology is being heralded as the key to new cancer treatments, energy independence, [...]

Oral Cancer Foundation News Team - A2012-04-09T18:41:44-07:00April, 2012|Oral Cancer News|

RNA molecules may help treat head/neck cancer

Source: www.drbicuspid.com Author: DrBicuspid Staff A nanoparticle drug delivery vehicle for small interfering RNA (ribonucleic acid) molecules (siRNA) shows promise for the treatment of head and neck cancer, according to a study published in the Journal of Controlled Release. Dong Shin, MD, of Emory University and Mark Davis, PhD, of the Nanosystems Biology Cancer Center at the California Institute of Technology had previously developed a nanoparticle that encapsulates a siRNA agent aimed at a protein known as RRM2. For this study they again collaborated to evaluate the effectiveness of these particles in head and neck cancer (JCR February 8, 2012). RRM2, when overexpressed in these tumor types, plays an active role in tumor progression and in the development of drug resistance, the researchers noted. Initial tests on head and neck tumor cells growing in culture showed that this construct was taken up by the tumor cells, and as a result growth of the cells was inhibited substantially. Based on these findings, the researchers tested a siRNA-loaded nanoparticle in a mouse model of human head and neck cancer. One intravenous injection of the drug shut down production of RRM2 for at least 10 days, with the nanoparticle being present in the tumor for three days, they reported. Four injections given over 10 days triggered a substantial amount of tumor cell death and significantly reduced tumor progression. The researchers did not observe any adverse effects or changes in body weight during therapy. In addition, the drug had no effect on RRM2 production [...]

Oral Cancer Foundation News Team - A2012-04-09T18:25:12-07:00April, 2012|Oral Cancer News|

Exposure to Nicotine and Carcinogens among South Western Alaskan Native Cigarette Smokers and Smokeless Tobacco User

Source: AACR Journals Background Prevalence of tobacco use, both cigarette smoking and smokeless, including iqmik (homemade smokeless tobacco prepared with dried tobacco leaves mixed with alkaline ash), and tobacco-related cancer is high in Alaska Native people (AN). To investigate possible mechanisms of increased cancer risk we studied levels of nicotine and tobacco-specific nitrosamines (TSNA) in tobacco products and biomarkers of tobacco toxicant exposure in South Western AN people. Methods Participants included 163 cigarette smokers (CS), 76 commercial smokeless tobacco (ST), 20 iqmik, 31 dual CS and ST (DT) and 110 non-tobacco (NT) users. Tobacco use history, samples of tobacco products used and blood and urine samples were collected. Results Nicotine concentrations were highest in cigarette tobacco and TSNAs highest in commercial ST products. AN participants smoked on average 7.8 cigarettes per day (CPD). Nicotine exposure, assessed by several biomarker measures, was highest in iqmik users, and similar in ST and CS. TSNA exposure was highest in ST users, and polycyclic aromatic hydrocarbon exposure highest in CS. Conclusions Despite smoking fewer CPD, AN CS had similar daily intake of nicotine compared to the general US population. Nicotine exposure was greatest from iqmik, likely related to high pH due to preparation with ash suggesting high addiction potential compared to other ST products. TSNA exposure was much higher with ST compared to other product use, possibly contributing to high rates of oral cancer. Impact Our data help understanding high addiction risk of iqmik use and cancer-causing potential of various forms of tobacco use [...]

Charlotte Parker2012-04-09T09:31:27-07:00April, 2012|Oral Cancer News|

Snus spat erupts in Norway

Source: Ice News A row has erupted over snuff tobacco in Norway after a state researcher said the government should be promoting it as a way of stopping smoking. Health officials have dismissed the criticisms of Karl Erik Lund, however, saying the substance, known as snus in Norway, is highly addictive and can cause cancer. Mr Lund, of the state institute for alcohol and drug research SIRUS, told Aftenposten newspaper that Norway should start being honest with its people by telling them that snus is “much less dangerous” than smoking. Dr Maja-Lisa Løchen, a professor of preventive medicine at the Univerity of Tromsø, however, told the newspaper that she was “furious” that they had given the story “so much space”. “No research has documented that using snus is an effective way to stop smoking,” Dr Løchen told Aftenposten. “On the contrary, some smokers can wind up using both forms of tobacco.” Løchen added that users, who usually place the snus under their lips to absorb the nicotine, also risk contracting other forms of cancer. She added that the health ministry would not be recommending the product. Snus is banned in many European countries but has a long tradition of use in Norway and Sweden where it is still legal. This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Charlotte Parker2012-04-06T09:53:42-07:00April, 2012|Oral Cancer News|

Swedish Match Announces Market Expansion for General Snus

Swedish Match today announced it has expanded into 7 additional US markets with its General brand Swedish snus. General is the number #1 selling snus in the world and the flagship brand for Swedish Match. Now General will be available in convenience stores and tobacco outlets in the metropolitan areas of New York, Los Angeles, Minneapolis, Phoenix, Denver, Nashville and throughout the state of Ohio with its two new flavors in the product assortment, Nordic Mint and Classic Blend. Those flavors were launched in Chicago, Dallas and Philadelphia in mid-2011. "These particular markets were chosen because they meet a number of important criteria to maximize the success of the General brand - from local smoking restrictions to the number of adult tobacco consumers and the potential opportunity for the snus category as a whole," according to Clark Darrah, Vice President Next Generation Products. General is authentic Swedish snus crafted from a sophisticated blend of premium tobaccos using a unique GothiaTek® production process ensuring the highest measure of quality. Snus is sold in pouches that are placed inconspicuously under the user's upper lip, and is a form of smokefree and spit free tobacco that is popular among white-collar professionals throughout Scandinavia, where it first originated in the early 19th century. While the category is still young in the United States, snus has enjoyed tremendous growth of over 225% since its first introduction domestically in 2006 and is now about 6% of the smokeless tobacco category. Darrah adds, "Adult tobacco consumers are [...]

Charlotte Parker2012-04-06T09:44:02-07:00April, 2012|Oral Cancer News|

The Gardasil Problem: How The U.S. Lost Faith In A Promising Vaccine

Source: Forbes Magazine, written by Matthew Herper Neal Fowler, 50, the chief executive officer of a tiny biotech called Liquidia, was assuming a position common to road-warrior entrepreneurs: leaning his elbows on the seat-back tray in an airplane so he could gaze at the screen of his laptop. That’s when he felt the lump in his neck. Fowler, a pharmacist, figured his lymph node was swollen by a recent cold, but the oncologist seated next to him—his chairman of the board—thought they’d better keep an eye on it. The chairman was right. Over the next week the lymph node got bigger and harder. It was not sore to the touch, as happens during a cold. Fowler went to the doctor, then a specialist who knew exactly what he was seeing: a new form of throat cancer that ear, nose and throat specialists across the U.S. now say dominates their practices. Some 8,000 of these tonsil tumors turn up each year nationwide, courtesy of strain 16 of the human papilloma virus—the same sexually transmitted virus that causes cervical cancer. Usually transmitted when men perform oral sex on women, it can also spread through other forms of contact, perhaps even just kissing. His prognosis was good—80% of those with this new tumor survive. His status as a drug industry veteran and chief executive of a biotechnology company didn’t hurt, either. He went from diagnosis to having the primary tumor removed from his tonsil in just a day. His first team of doctors [...]

Charlotte Parker2012-04-05T21:25:34-07:00April, 2012|Oral Cancer News|

Declines in Smoking and Lung Cancer Mortality in the U.S.: 1975–2000

Source: Oxford Journals Although changing smoking behaviors have had a major impact on lung cancer mortality in the U.S., the numbers of lung cancer deaths averted are only a small fraction of deaths that could have been avoided had all smoking ceased following the 1964 Surgeon General’s Report. Further efforts to control tobacco use are needed to decrease the impact of the disease, according to a study published March 14 in the Journal of the National Cancer Institute. The restrictions on smoking in public places, escalations in cigarette taxes, reduced access to cigarettes, and an increased public awareness on the health issues related to smoking have all helped steadily decrease the number of smokers in the U.S. since the mid 1950’s; however, little measurable information exists in regards to the amount lung cancer deaths have diminished in association with the decline in smoking. In order to determine the effect that reduced tobacco smoking has had on lung cancer mortality in the U.S., Suresh H. Moolgavkar, M.D., Ph.D., of the Program in Biostatistics and Biomathematics at the Fred Hutchinson Cancer Research Center in Seattle, Washington and colleagues built independent models based on cohort, case-control, or registry data and adjusted to overall mortality to estimate the number of lung cancer deaths prevented between 1975–2000. The data were distinguished by sex and birth decade (1890–1970), and the prevalence of smoking and lung cancer deaths were considered based on actual tobacco control (ATC), historical changes in smoking rates, no tobacco control (NTC), predicted smoking [...]

Charlotte Parker2012-04-04T09:10:41-07:00April, 2012|Oral Cancer News|

The 795 Thousand and Ending a Century of Tobacco

Source: Oxford Journals Tonight, a grandfather will read his grandson a soothing bedtime story. Yesterday, a mother saw her son perform a brilliant violin solo. Tomorrow, a grandfather will see his granddaughter complete the first unassisted triple play in their community's t-ball league history. What do these vignettes have in common? They represent just three of the 795 851 people––the 795 thousand––whose premature deaths from lung cancer were averted in the United States through aggressive tobacco control policies and interventions between 1975 and 2000, as determined by a series of consortium-based sophisticated modeling techniques and reported by Moolgavkar et al. (1) in this issue of the Journal. Sometimes, we become inured to the sheer number of deaths caused by tobacco—for example, a predicted 1 billion tobacco-caused deaths this century, 100 million people killed by tobacco in the 20th century, 6 million deaths per year globally, 443 000 deaths per year in the United States, etc. But, despite these enormous, and even numbing, numbers, we need to remember that every one of these 1 billion, 100 million, 6 million, or 443 000, was a father, mother, brother, sister, son, or daughter who, if tobacco had not intervened, would have enjoyed, and shared, a longer, healthier, and more fulfilling life. How did this happen? How did we allow tobacco, over the past 100 years, to kill and cause disease with such abandon? And, more important, how have we begun to turn the tide against the tobacco tsunami and how can we continue to learn from [...]

Charlotte Parker2012-04-04T08:27:45-07:00April, 2012|Oral Cancer News|

Head And Neck Cancer Chemotherapy Efficacy Boosted By Human Virus

Source: MedicalNewsToday.com Preliminary data from a trial published in Clinical Cancer Research shows that a harmless human virus that occurs naturally could potentially boost the effects of two standard chemotherapy drugs in some cancer patients. Oncolytics Biotech Inc. developed a new drug, RT3D that will be marketed under the trade name of Reolysin. The drug is based on a virus, i.e. reovirus type 3 Dearing that is commonly found in the respiratory and gastrointestinal tracts of almost every adult without causing any symptoms. RT3D can grow and kill certain types of cancer cells, but it does not grow in normal cells. Earlier trials whereby patients were injected with only the virus displayed limited effectiveness, however, the team discovered that the effects of platin and taxane-based chemotherapy on tumor cells seemed to be magnified by RT3D. Dr Kevin Harrington and his team decided to start a clinical trial in which they examined intravenous RT3D in combination with chemotherapeutics carboplatin and paclitaxel in 31 patients with advanced cancers that had become unresponsive to standard treatments. They conducted an initial Phase I study in patients with a variety of advanced cancers, which demonstrated that the drug combination was safe, with generally mild side effects that were consistent with chemotherapy alone. The best responses were observed in patients with head and neck cancers, including tumors of the nasal cavity, eye, tongue, gums, lip, cheeks, voice box and esophagus. Worldwide, each year about 650,000 people are diagnosed with squamous cell cancer of the head and [...]

Charlotte Parker2012-04-03T10:50:41-07:00April, 2012|Oral Cancer News|

High purity zirconia improves speech valves

Source: www.onlinetmd.com Author: Elizabeth Engler Modic Morgan Technical Ceramics (MTC) worked with the UK-based University of Hull to develop a new valve used to restore vocal function for patients with throat cancer. The new tracheo-oesophageal fistula speech valve uses Zyranox biocompatible Yttria partially-stabilized Zirconia, specifically developed for surgical implant devices. The iterative design process for this innovative valve included a close collaboration, featuring consultation on materials, prototyping to test the design, and precision manufacturing to meet the extremely tight tolerances required. The patented new ceramic valve lasts at least eight times longer than traditionally used silicone valves, improving patient quality of life and decreasing overall healthcare costs. The device is to go to market via the spinout company Avoco Medical Ltd. Project Goals Avoco Medical was seeking to improve upon a commonly used speech restoration system for throat cancer patients, which uses a small silicone valve connecting the windpipe (trachea) and the throat (oesophagus). Air, powered by the lungs, diverts into the throat, which vibrates and results in fluent speech. Traditionally the valve is from silicone rubber, but the material exposure to hostile and non-sterile environments results in development of a biofilm on the surface. This biofilm causes valve performance to deteriorate, necessitating an uncomfortable and costly valve replacement procedure about every three months.[1] Precision Manufacturing The company was seeking a way to replace the silicone with ceramic, a more attractive material because of its stability, biocompatibility, and compliance. With its hard, impervious surface, ceramic is more resistant [...]

Oral Cancer Foundation News Team - A2012-04-03T09:21:12-07:00April, 2012|Oral Cancer News|